The Uromigos
The Uromigos
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Μην παραλείψεις να επισκεφτείς τη σελίδα του podcast και να στηρίξεις τον δημιουργό: www.uromigos.org
Δημιουργός
The Uromigos
Κατηγορία
Ιστοσελίδα του podcast
Τελευταίο επεισόδιο
5 Οκτ 2026
Πού να ακούσεις;
Podcast στην εφαρμογή Replaio Radio Έρχεται σύντομαΤα podcast έρχονται σύντομα στην εφαρμογή. Εγκατάστησέ την τώρα και δες πρώτος μια εντελώς νέα προσέγγιση στα podcast
Επεισόδια
Episode 342: ESMO 2024 Preview with Silke Gillessen 03.09.2024 32:24
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
Episode 341: Hormone Resistance in Prostate Cancer 27.08.2024 33:05
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
Episode 340: Cancer Immunity Cycle Update 19.08.2024 41:50
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU 09.08.2024 18:37
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More 06.08.2024 25:39
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
Episode 337: Updated NCCN Guidelines in RCC 30.07.2024 42:38
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 24.07.2024 35:35
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
Episode 335: Novel immune therapies for renal cancer 19.07.2024 37:31
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
Episode 333: The Uromigos Cup - The Netherlands 05.07.2024 26:20
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
Episode 332: The Uromigos Cup - Germany's Entry 26.06.2024 35:55
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
Episode 331: AUA 2024 NMIBC Highlights 21.06.2024 33:56
Aditya Bagrodia describes three new drugs/studies in NMIBC.
Episode 330: ASCO 2024 Highlights 10.06.2024 52:47
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies 05.06.2024 26:32
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates 04.06.2024 24:02
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
Episode 326 ASCO24: KIM-1 in Renal Cancer 03.06.2024 18:08
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer 03.06.2024 33:44
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC 02.06.2024 20:43
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
Episode 323 ASCO24: TDXD in Bladder Cancer 02.06.2024 29:47
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC) 02.06.2024 22:16
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original? 01.06.2024 23:25
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
Episode 320: Team Canada's entry for the Uromigos Cup 25.05.2024 23:30
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
Episode 319: ASCO 2024: A Preview of GU Data 19.05.2024 33:49
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases 13.05.2024 31:59
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
Episode 317: AUA 2024 Preview with the AUA Secretary 01.05.2024 22:16
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
Episode 316: APCCC 2024 Summary with Silke Gillessen 28.04.2024 41:11
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
Παρόμοια podcast
Το Replaio δεν είναι εκδότης podcast - τα ονόματα των εκπομπών, τα εξώφυλλα και ο ήχος ανήκουν στους δημιουργούς τους και διανέμονται μέσω δημόσιων ροών RSS